Experienced in Autoimmune Hemolytic Anemia

Dr. Srdan Verstovsek

Oncology | Hematology Oncology
1515 Holcombe Blvd, 
Houston, TX 
 (1176.9 mi)
Clinical Trials:Currently Recruiting for 1 Trial
29 Years of Experience
Experienced in Autoimmune Hemolytic Anemia
1515 Holcombe Blvd, 
Houston, TX 
 (1176.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Srdan Verstovsek is an Oncologist and a Hematologist Oncology provider in Houston, Texas. Dr. Verstovsek has been practicing medicine for over 29 years and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 490 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Autoimmune Hemolytic Anemia.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drug: TL-895
Study Phase: Phase 2
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: IFN-alpha2a
Study Phase: Phase 2
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Phase: Phase 2
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: August 26, 2024
Intervention Type: Other, Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2024
Intervention Type: Drug
Study Drug: GB2064
Study Phase: Phase 2
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 2
Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Enrollment Status: Terminated
Publish Date: May 15, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 8 Less Clinical Trials

490 Total Publications

Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.
Journal: Future oncology (London, England)
Published: July 29, 2024
Similar Doctors
Distinguished in Autoimmune Hemolytic Anemia
Dr. Thein H. Oo
Hematology Oncology | Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Thein H. Oo
Hematology Oncology | Hematology | Oncology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
713-792-6127
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thein Oo is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Oo and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Pernicious Anemia, Thrombocytopenia, Drug-Induced Thrombocytopenia, and Venous Thromboembolism (VTE). Dr. Oo is currently accepting new patients.

Advanced in Autoimmune Hemolytic Anemia
Dr. Cristhiam M. Rojas-Hernandez
Hematology | Oncology | Hematology Oncology
Advanced in Autoimmune Hemolytic Anemia
Dr. Cristhiam M. Rojas-Hernandez
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (0.6 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cristhiam Rojas-Hernandez is a Hematologist and an Oncologist in Houston, Texas. Dr. Rojas-Hernandez and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Thrombocytopenia, Pulmonary Embolism, Drug-Induced Thrombocytopenia, Adult Immune Thrombocytopenia, and Thrombectomy.

Advanced in Autoimmune Hemolytic Anemia
Dr. Alexander C. Wong
Oncology | Hematology
Advanced in Autoimmune Hemolytic Anemia
Dr. Alexander C. Wong
Oncology | Hematology
16659 Southwest Fwy, Suite 581, 
Sugar Land, TX 
 (16.3 mi)
281-491-0561
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexander Wong is an Oncologist and a Hematologist in Sugar Land, Texas. Dr. Wong and is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Autoimmune Hemolytic Anemia. Dr. Wong is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile